Table 5 Microbiological Cure or Eradication in Secondary Bacteremia Patients Receiving C/T
From: Ceftolozane/tazobactam for the treatment of bacteremia: a systematic literature review (SLR)
Author, year | Study design | Source | Pathogen type | Antibiotic resistance | Outcome definition | Time point | % (n/N) Reporting cure or eradication |
|---|---|---|---|---|---|---|---|
Single-arm trial | |||||||
 Arakawa et al., 2019 [32] | Single-arm trial | Mixed infections: uncomplicated pyelonephritis and cUTI | – | – | Negative blood culture | 14 days | 95.7% (22/23) |
 Arakawa et al., 2019 [32] | Single-arm trial | Mixed infections: uncomplicated pyelonephritis and cUTI | – | – | Negative blood culture and a urine culture shows all uropathogens (> = 10^5 CFU/ml) found at baseline were decreased to < 10^4 CFU/ml | 14 days | 78.3% (18/23) |
Retrospective cohort studies | |||||||
 Caston et al., 2017 [14] | Retrospective cohort | Overall mixed infection and bacteremia Mixed infections: abdominal (N = 1), respiratory (N = 3) and venous central catheter (N = 1) | Pseudomonas: 100% (not further specified) | MDR infection: 100% | – | 30 days (after therapy with C/T) | 80.0% (4/5) |
 Gallagher et al., 2018 [17] | Retrospective cohort | Mixed, bone/ joint, intra-abdominal, pneumonia, wound, and UTI | Pseudomonas: 100% (not further specified) | MDR infection: 100% | Defined as a negative culture at the end of therapy | – | 68.0% (13/19) |
 King et al., 2018 [11] | Retrospective cohort | Overall Mixed infections: pneumonia (N = 8), UTI (N = 7), intra-abdominal (N = 4), wound (N = 1) | Pseudomonas: 100% (not further specified) | MDR infection: 100% | Microbiological success required a negative culture at the end of therapy | – | 72.2% (13/18)a |